Literature DB >> 3734850

Grading of neurotoxicity in cancer therapy.

A M Castellanos, W S Fields.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3734850     DOI： 10.1200/JCO.1986.4.8.1277

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Phase I study of mitonafide with a 3-day administration schedule: early interruption due to severe central nervous system toxicity.

Authors:  E Díaz-Rubio; M Martín; J M López-Vega; A Casado; A Benavides
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

2.  Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer.

Authors:  R Rosell; J Carles; A Abad; N Ribelles; A Barnadas; A Benavides; M Martin
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

3.  Phase I study of mitonafide in solid tumors.

Authors:  M Llombart; A Poveda; E Forner; C Fernández-Martos; C Gaspar; M Muñoz; T Olmos; A Ruiz; V Soriano; A Benavides
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

4.  Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity.

Authors:  J L Abbruzzese; S Schmidt; M N Raber; J K Levy; A M Castellanos; S S Legha; I H Krakoff
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

5.  Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies.

Authors:  S Leyvraz; R Herrmann; L Guillou; H P Honegger; A Christinat; M F Fey; C Sessa; M Wernli; T Cerny; D Dietrich; B Pestalozzi
Journal:  Br J Cancer       Date:  2006-10-10       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.